A phase III clinical trial data published May 2 in Cell Reports Medicine found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with glioblastoma.
The FY24 Defense Appropriations Act provides funding for the Glioblastoma Research Program to support research of high potential impact and exceptional scientific merit to reduce the burden of glioblastoma on service members and their families, veterans, and the American public. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.
